We expect stable sales in the Duphaston brand and an increase in volume in the Thyronorm brand to result in revenue and PAT CAGR of 11.1% and 11.3% respectively 0ver FY21-FY24E. However, considering rich valuations (PE 40x for FY24E), we recommend HOLD with a target price of Rs 18,000/share.